Ceryvyn TherapeuticsASX:CYV -7.69% EV-to-EBITDA is -0.27 as of Jul. 11, 2026. The stock has 3 warning signs investors should review. Among 392 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 255101.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ceryvyn Therapeutics's enterprise value is A$53.17 Mil.
Ceryvyn Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was A$-194.20 Mil. Therefore, Ceryvyn Therapeutics's EV-to-EBITDA for today is -0.27.
The historical rank and industry rank for Ceryvyn Therapeutics's EV-to-EBITDA or its related term are showing as below:
ASX:CYV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.39 Med: -5.26 Max: 0.49
Current: -0.27
During the past 13 years, the highest EV-to-EBITDA of Ceryvyn Therapeutics was 0.49. The lowest was -22.39. And the median was -5.26.
ASX:CYV's EV-to-EBITDA is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 12.935
vs ASX:CYV: -0.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ceryvyn Therapeutics's PE Ratio (TTM) for today is calculated as:
Ceryvyn Therapeutics's share price for today is A$0.012.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ceryvyn Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was A$-0.209.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ceryvyn Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CYV vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Ceryvyn Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ceryvyn Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics's EV-to-EBITDA falls into.
Ceryvyn Therapeutics's current Enterprise Value is A$53.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ceryvyn Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was A$-194.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ceryvyn Therapeutics (ASX:CYV) has a EV-to-EBITDA of -0.27 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ceryvyn Therapeutics. According to the industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 392 companies in the Biotechnology industry.
Is Ceryvyn Therapeutics' EV-to-EBITDA too high?
Ceryvyn Therapeutics' current EV-to-EBITDA is -0.27. Based on the distribution chart, Ceryvyn Therapeutics ranks #999999 out of 392 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #999999 out of 392 companies for EV-to-EBITDA. This places Ceryvyn Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.94, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ceryvyn Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current EV-to-EBITDA is -0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current EV-to-EBITDA of -0.27. The current EV-to-EBITDA is -0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current EV-to-EBITDA is -0.27 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYV has been successfully added to your 